“Who am I?” A qualitative meta-synthesis of Chemotherapy‐induced alopecia and body image perception in breast cancer patients

Koçan, Sema; Aktuğ, Cemile; Gürsoy, Ayla

doi:10.1007/s00520-023-07704-8

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These adverse effects have consistently ranked high on the lists of most challenging concerns from the patient's perspective for the past four decades. [50][51][52] Considerably varying preferences towards the benefits and risks of treatment were observed among individual patients. Interestingly, our review revealed that some patients demonstrated a willingness to undergo treatments that conferred relatively small survival benefits, but with significant risk or toxicity.…”

Section: Discussionmentioning

confidence: 99%

Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review

Yeo,

Liew,

Chan

et al. 2023

PPA

View full text Add to dashboard Cite

Objective: Conventionally, optimal treatment strategies for breast cancer have been largely determined by physicians, with a scant understanding of patients' treatment values and preferences. Incorporating patient preferences in the decision-making process for breast cancer treatment is gaining recognition and can potentially improve treatment outcomes and compliance. This scoping review aims to synthesize evidence on the key determinants that are most valued by breast cancer patients when deciding on their treatment options. Methods: We searched three electronic databases (PubMed/MEDLINE, SCOPUS, and CINAHL Plus) utilizing a systematic scoping review method. Two reviewers independently screened, applied inclusion criteria, reviewed, and synthesized findings. A mixedmethod narrative approach combining the inductive thematic analysis and content analysis methodologies was used to synthesize and summarize the findings. Results: The review included 22 studies, leading to the conceptualization of 5 overarching themes and 17 sub-themes. Among these, the most frequently cited theme was treatment benefits, followed by treatment-related process, treatment-related risk, quality of life, and cost of treatment. Women with breast cancer highly value treatments that offer good effectiveness, prolong survival, prevent recurrence, and maintain quality of life. Patient concerns include treatment-related side effects, safety, the risk of secondary cancer, and direct or indirect out-of-pocket costs. Additionally, patients also consider treatment duration, mode of administration, physician recommendation, and treatment availability and accessibility when deciding on their preferred treatment. Conclusion:The evidence synthesized in this review offers insights into refining breast cancer treatment strategies to align more closely with patient values. Recognizing and integrating patient perspectives in breast cancer care could potentially lead to improved treatment outcomes, enhanced patient compliance, and more personalized care. Healthcare professionals are encouraged to incorporate these key determinants in their treatment decision-making processes, aiming to deliver a patient-centered care that aligns with the unique preferences and values of each patient.Plain Language Summary: Breast cancer is a significant health concern, and treatment decisions have traditionally driven by physicians, often without due consideration for patients' preferences in their treatment choices. This scoping review aimed to explore and summarize what matters most to breast cancer patients when deciding on their treatment options. We found five main themes that were important to patients:(1) Effectiveness: Patients highly value treatments that are effective in fighting cancer, prolonging survival, and preventing recurrence.(2) Treatment-related process: The length of treatment and availability of different therapies influenced patients' choices. Patients trust their doctors' expertise but also value being involved in the decision-making process to have t...

show abstract

Section: Discussionmentioning

confidence: 99%

Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review

Yeo,

Liew,

Chan

et al. 2023

PPA

View full text Add to dashboard Cite

show abstract

“…In the context of developing interventions for patients with CIA, it is essential to consider the consequences, concerns, and emotional responses of patients to help them cope with hair loss [ 7 ]. Therefore, it is crucial to use valid quantitative measures to assess distress, including worry and emotional response [ 6 , 7 ], to gain a comprehensive understanding of the impact of CIA on patients.…”

Section: Introductionmentioning

confidence: 99%

“…It has been reported as the third most burdensome adverse event in treating gynecological and breast cancer [3][4][5]. Patients with higher distress related to cancer treatment-associated alopecia are 1.5 times more likely to suffer from depression than those with lower distress [4,6]. In the context of developing interventions for patients with CIA, it is essential to consider the consequences, concerns, and emotional responses of patients to help them cope with hair loss [7].…”

Section: Introductionmentioning

confidence: 99%

Validation and responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in breast cancer patients

Kraehenbuehl,

Kang,

Bang

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose This study aimed to validate the Chemotherapy-Induced Alopecia Distress Scale (CADS) in a diverse English-speaking population and patients with endocrine treatment-induced alopecia (EIA). Objective Chemotherapy and endocrine therapy commonly cause alopecia in breast cancer patients, leading to significant psychological and social challenges. The CADS was developed to assess the psychosocial impact of alopecia, but its generalizability beyond Korean patients requires further investigation. Methods Data from the CHANCE study (NCT02530177), which focused on non-metastatic breast cancer, was used. The cohort included 256 patients, and CADS data were collected at baseline, 6 months after chemotherapy completion, or 12 months after initiating endocrine therapy. The CADS questionnaire comprised 17 items covering physical and emotional health, daily activities, and relationships. Reliability was assessed using Cronbach’s alpha, and responsiveness was measured by effect size. Results The CADS exhibited good reliability, with Cronbach’s alpha of 0.91 for the overall score, indicating acceptable internal consistency in both chemotherapy (0.89) and endocrine therapy (0.86) groups. Longitudinal responsiveness was supported by an effect size of 0.49 between decreasing satisfaction with hair growth and increasing emotional distress. Cross-sectional validity was confirmed, with effect sizes of 0.91 and 0.92 for satisfaction with hair growth and emotional and activity domains, respectively. Conclusion The CADS is a valid and responsive tool for assessing the psychosocial impact of chemotherapy-induced alopecia and endocrine treatment-induced alopecia in a diverse Western patient population.

show abstract

Symptom network and quality of life of breast cancer patients receiving multimodal cancer treatment: Cross-sectional study

Kim,

Lee,

Byun

et al. 2024

European Journal of Oncology Nursing

View full text Add to dashboard Cite

“Who am I?” A qualitative meta-synthesis of Chemotherapy‐induced alopecia and body image perception in breast cancer patients

Cited by 5 publications

References 34 publications

Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review

Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review

Validation and responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in breast cancer patients

Symptom network and quality of life of breast cancer patients receiving multimodal cancer treatment: Cross-sectional study

Contact Info

Product

Resources

About